Jpmorgan Chase & CO Regenxbio Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Regenxbio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,012,476 shares of RGNX stock, worth $26.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,012,476
Previous 3,722,553
19.08%
Holding current value
$26.4 Million
Previous $78.4 Million
55.06%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding RGNX
# of Institutions
199Shares Held
43.3MCall Options Held
58.9KPut Options Held
58.4K-
Black Rock Inc. New York, NY8.61MShares$75.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$44.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.57MShares$40 Million3.49% of portfolio
-
State Street Corp Boston, MA2.87MShares$25.2 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.3MShares$11.4 Million0.75% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $379M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...